Drug Trial Radar · NCT00413699
Long-Term Effectiveness And Safety Of CP-690,550 For The Treatment Of Rheumatoid Arthritis
Last checked: Nov 20, 2026Latest source record: Oct 30, 2018 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
4,488
Actual
Start
Feb 5, 2007
Primary completion
Nov 30, 2016
Study completion Oct 26, 2017
Sponsor
- Lead sponsor
- PfizerPfizer (PFE)
- Sponsor type
- Industry
- First posted
- Dec 20, 2006
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Non randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to determine the long-term effectiveness and safety of CP-690,550 for the treatment of rheumatoid arthritis. Subjects are eligible for this study only after participating in another "qualifying" study of CP-690,550 A sub-study will be conducted within the A3921024 study, this study will evaluate the immune response to pneumococcal and influenza vaccines in patients receiving CP-690,550
Conditions
- Arthritis, Rheumatoid
Interventions
CP-690,550Drug
5 mg PO BID open label; may increase to 10 mg PO BID to provide greater control of RA if no related AEs are present. May be off study drug temporarily for up to 28 days for mild to moderate AEs.
CP-690,550Drug
10 mg PO BID open label; may decrease to 5 mg PO BID for mild to moderate AEs. May be off study drug temporarily for up to 28 days for mild to moderate AEs.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Initial Period: Primary Endpoints Were Standard Laboratory Safety Data (Chemistry, Hematology, Etc.) and Adverse Event (AE) ReportsTime frame: Includes laboratory test abnormality data for all visits and adverse event data up to 999 days after last dose of study drug
- Extension Period: Number of Participants With Treatment Emergent Adverse Events (AEs), Serious Adverse Events (SAEs)Time frame: Baseline (Day 1 at Entry of Extension Period) up to 28 days after last study drug dose in Extension Period (13 Months)
- Extension Period: Number of Participants With Laboratory Test AbnormalitiesTime frame: Baseline (Day 1 at Entry of Extension Period) up to 28 days after last study drug dose in Extension Period (13 Months)
- Initial Period: The Long Term Safety and Tolerability of CP-690,550 5 Milligrams (mg) Twice Daily (BID) and 10 mg BID for the Treatment of Rheumatoid ArthritisTime frame: Includes AEs for every visit and up to 999 days after last dose of study drug
- Extension Period: Percentage of Participants With Adverse Events and Who Discontinued Treatment Due to Adverse Events to Assess Long-term Safety and Tolerability of TofacitinibTime frame: Baseline (Day 1 at Entry of Extension Period) up to Month 6 of Extension Period; Month 6 of Extension Period to Month 12 of Extension Period
Locations
469 sites in 43 countries. Site status is shown where the registry gives one.
University of Alabama at Birmingham
Birmingham, Alabama
Rheumatology Associates of North Alabama, PC
Huntsville, Alabama
Arthrocare, Arthritis Care & Research, PC
Gilbert, Arizona
Arizona Arthritis & Rheumatology Associates, P.C.
Phoenix, Arizona
Radiant Research, Inc.
Scottsdale, Arizona
Catalina Pointe Clinical Research
Tucson, Arizona
CHI St. Vincent Medical Group Hot Springs
Hot Springs, Arkansas
NEA Baptist Clinic
Jonesboro, Arkansas
Osborne Research Center, LLC
Little Rock, Arkansas
Little Rock Diagnostic Clinic, PA
Little Rock, Arkansas
Med Investigations, Inc.
Fair Oaks, California
Talbert Medical Group
Huntington Beach, California
University of California San Diego Center for Innovative Therapy
La Jolla, California
Keck Medicine of USC
Los Angeles, California
University of Southern California (USC) Norris Comprehensive Cancer Center-
Los Angeles, California
University of Southern California (USC) Norris Comprehensive Cancer Center
Los Angeles, California
Ronald Reagan UCLA Medical Center, Drug Information Center
Los Angeles, California
University of California Los Angeles
Los Angeles, California
Stanford University School of Medicine
Palo Alto, California
Office of Anupama Bhat, MD
Roseville, California
San Diego Arthritis Medical Clinic
San Diego, California
Pacific Arthritis Center Medical Group
Santa Maria, California
Stanford Health Services - Medical Specialty Clinics
Stanford, California
Inland Rheumatology Clinical Trials, Inc.
Upland, California
Boulder Medical Center, PC
Boulder, Colorado
Arthritis Associates and Osteoporosis Center of Colorado Springs
Colorado Springs, Colorado
University of Connecticut Health Center
Farmington, Connecticut
Arthritis & Osteoporosis Center, PC
Hamden, Connecticut
New England Research Associates, LLC
Trumbull, Connecticut
Delaware Arthritis and Osteoporosis Center
Newark, Delaware
Arthritis and Rheumatic Disease Specialties
Aventura, Florida
Allergy, Asthma, Arthritis, & Lung
Daytona Beach, Florida
Physicians Research Alliance LLC
DeBary, Florida
Southeastern Arthritis Center
Gainesville, Florida
Southeastern Imaging and Diagnostics
Gainesville, Florida
Southeastern Integrated Medical PL d/b/a Florida Medical Research Institute
Gainesville, Florida
Southeastern Integrated Medical, PL, d/b/a Florida Medical Research Institute
Gainesville, Florida
Jacksonville Center for Clinical Research
Jacksonville, Florida
Florida Arthritis Center, P.L.
Lake Mary, Florida
BayCare Outpatient Imaging at Bardmoor
Largo, Florida
Showing 40 of 469 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.